/ Print /


Readmission Cost Savings are a Reality with Enhanced Patient EngagementReduce readmissions by focusing on better engagement with patients and improving coordination from inpatient to outpatient settings.
Migraine Pipeline and Impact Updates: What Health Execs Should KnowA new report highlights physical, social, and economic challenges of migraine.
Will UnitedHealthcare’s Direct-to-Consumer Pharma Rebates Curb Rising Costs?UnitedHealthcare will pass on pharmacy discounts directly to some consumers, signaling the next wave of disruption in healthcare, say industry watchers.
HIV Pipeline Prospects Getting HealthierThere is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Cigna-Express Scripts Deal: 5 Takeaways for Health ExecsThe Cigna-Express Scripts deal may signal a move to more vertical and horizontal healthcare deals. Here’s what else it means.
Four New Ways to Approach Opioid Use DisordersA new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage
Scammers, Fraudsters Capitalize on Opioid Addiction TreatmentA lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.
What Roche’s Purchase of Flatiron Health Means for Health ExecsSwitzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.
Walgreens-AmerisourceBergen Deal: 3 TakeawaysRetail drug chain giant Walgreens made a takeover approach to drug distributor AmerisourceBergen. Here’s what industry watchers want you to know about it.
Report Slams 340B Drug Discount ProgramA Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.